Oxidien Pharmaceuticals Announce Addition to Scientific and Medical Advisory Board

UF Innovate | The Hub resident client Oxidien Pharmaceuticals, a clinical-stage biopharmaceutical company developing a best-in-class enzyme therapeutic for an underserved kidney disease indication, announced three additions to its Scientific and Medical Advisory Board (SMAB) to provide external advice on its development activities and clinical program in secondary hyperoxaluria.

Helena Cowley, CEO of Oxidien, said “The strengthening of our Scientific and Medical Advisory Board is very significant at this stage in our development and will provide for additional expertise in strategic development decisions. Each board member brings a wealth of knowledge, experience, and a complementary external perspective. We look forward to working with them.”